AimedBio
received approval from the Korea Exchange for its listing on the KOSDAQ market.
The approval was granted less than two months after AimedBio submitted its
application in July, signaling a notably swift review process. With this
milestone achieved, the company plans to file its securities registration
statement in the coming weeks and formally initiate its initial public offering
(IPO) process. Mirae Asset Securities is serving as the lead underwriter.
As part of its application under the special technology-based listing track, AimedBio
earned “A” ratings from two accredited evaluation institutions—underscoring the
company’s technological innovation and commercial potential.
In advance of the IPO, AimedBio also raised approximately 38 million USD in a
pre-IPO funding round, bringing its total funding to date to 82 million USD.
“The listing marks only the beginning. Our next chapter is about scaling
rapidly, strengthening global partnerships, and positioning AimedBio as a
leading force in the global biotech industry" said Nam-Gu Her, CEO of AimedBio.
Link to full
article: https://www.koreabiomed.com/news/articleView.html?idxno=29046